Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
Acquiring Company
Genezen
Acquired Company
uniQure
Indianapolis
NetherlandsManufacturingBiotechnologyManufacturingBiotechnologyHealth CareGeneticsTherapeuticsDescription
Genezen, a best-in-class gene therapy CDMO, has announced an agreement to acquire uniQure's commercial gene therapy operations in Lexington, MA. This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world.
Quick answer
Genezen is acquiring uniQure, announced July 1, 2024. Genezen is based in Indianapolis, Indiana, United States.
- How much did Genezen pay for uniQure?
- The deal value was not disclosed.
- What does Genezen do?
- Genezen is a rapidly growing top-tier CDMO with over a decade of experience and state-of-the-art viral vector manufacturing facilities.
- Where are Genezen and uniQure based?
- Genezen is based in Indianapolis, Indiana, United States. uniQure is based in Netherlands.
- Who are the decision-makers at Genezen?
- Fundz holds 1 contact at Genezen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Genetics and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (August 9, 2024)
- Edwards Lifesciences Completes Acquisitions of JenaValve Technology and Endotronix (July 24, 2024)
- Lantheus Holdings, Inc. acquires Meilleur Technologies, Inc. to expand Alzheimer’s diagnostic capabilities (July 15, 2024)
- Merck completes acquisition of EyeBio to diversify its late-stage pipeline (July 12, 2024)
- AA Medical completes acquisition of Surgical Product Solutions, forming strategic partnership (July 11, 2024)
Who to call at Genezen, and when
When Genezen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Genezen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Genezen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Genezen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Genezen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired uniQure?
uniQure was acquired by Genezen, based in Indianapolis. The deal was reported on July 1, 2024. Genezen is a rapidly growing top-tier CDMO with over a decade of experience and state-of-the-art viral vector manufacturing facilities. Genezen is privately held and operates in Manufacturing.
When did Genezen acquire uniQure?
Genezen's acquisition of uniQure was reported on July 1, 2024. Genezen, a best-in-class gene therapy CDMO, has announced an agreement to acquire uniQure's commercial gene therapy operations in Lexington, MA. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does uniQure do?
uniQure has been a pioneer in gene therapy manufacturing for the past 15 years. It has a commercially-licensed viral vector facility and a world-class team of employees. It is publicly traded (QURE), operating in Manufacturing, and is based in Netherlands.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.